Lifesaving drug for infants costs $2.1 million a dose

Lifesaving drug for infants costs $2.1 million a dose

(HealthDay)—Its extremely high price tag means that a lifesaving medication to treat young children with spinal muscular atrophy is simply too expensive for most families.

A single dose of Zolgensma costs $2.1 million, the highest per-dose price ever, NBC News reported. That puts the —approved by the U.S. Food and Drug Administration in May—out of reach for many parents of infants with .

Sarah Stanger's son Duke has the illness. "I was pretty shocked" by the price, Stanger told NBC News. "You know, as a teacher we definitely don't have $2.1 million, and I don't know anybody who does." Her family's company refused to pay for the drug, which doctors said was the best option for Duke. "With no treatment, most children will pass away by age 2," Stanger said.

When Zolgensma was approved, maker Novartis said it expected would cover the cost of the treatment. The company told NBC News that a "wide range of patients" have had the drug covered by insurance and added that it is not uncommon for patients to have to go through an appeals process for any new drug.

Explore further

FDA approves $2M medicine, most expensive ever

More information: NBC News Article

Copyright © 2019 HealthDay. All rights reserved.

Citation: Lifesaving drug for infants costs $2.1 million a dose (2019, July 30) retrieved 8 March 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments